Advertisement
Advertisement
RARE
Ultragenyx Pharmaceutical Inc.
23.30
USDSponsored
-0.61
-2.57%
Apr 10, 15:59 UTC -4
Closed
After-Market
23.00
-0.30
-1.27%
RARE Earnings Reports
Positive Surprise Ratio
RARE beat 20 of 41 last estimates.
49%
Next Report
Date of Next Report
Apr 30, 2026
Estimate for Q1 26 (Revenue/ EPS)
$165.74M
/-$1.50
Implied change from Q4 25 (Revenue/ EPS)
-19.93%
/+16.28%
Implied change from Q1 25 (Revenue/ EPS)
+18.99%
/-4.46%
Ultragenyx Pharmaceutical Inc. earnings per share and revenue
On Feb 12, 2026, RARE reported earnings of -1.29 USD per share (EPS) for Q4 25, missing the estimate of -1.11 USD, resulting in a -15.82% surprise. Revenue reached 207.00 million, compared to an expected 200.91 million, with a 3.03% difference. The market reacted with a -1.07% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 15 analysts forecast an EPS of -1.50 USD, with revenue projected to reach 165.74 million USD, implying an increase of 16.28% EPS, and decrease of -19.93% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Ultragenyx Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Ultragenyx Pharmaceutical Inc. reported EPS of -$1.29, missing estimates by -15.82%, and revenue of $207.00M, 3.03% above expectations.
How did the market react to Ultragenyx Pharmaceutical Inc.'s Q4 2025 earnings?
The stock price moved down -1.07%, changed from $24.37 before the earnings release to $24.11 the day after.
When is Ultragenyx Pharmaceutical Inc. expected to report next?
The next earning report is scheduled for Apr 30, 2026.
What are the forecasts for Ultragenyx Pharmaceutical Inc.'s next earnings report?
Based on 15
analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$1.50 and revenue of $165.74M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement